February 23, 2024
Neuroendocrine Tumor Treatment

Neuroendocrine Tumor Treatment: A Guide To Understanding Treatment Options

Neuroendocrine tumors (NETs) are a rare type of cancer that can develop in tissues and organs that are part of the neuroendocrine system. These tumors can be challenging to diagnose and treat due to their unique biology and locations in the body. However, advances in research have led to improved treatment approaches and outcomes for patients with NETs in recent years.

What are Neuroendocrine Tumors?

Neuroendocrine tumors arise from specialized cells called neuroendocrine cells that are found throughout the body in organs like the lungs, stomach, intestines, pancreas and thyroid. These cells produce and secrete hormones and neurotransmitters that help regulate various bodily functions. NETs can occur anywhere neuroendocrine cells are present but they commonly develop in the lungs, appendix and small intestine. Symptoms vary depending on the size and location of the tumor as well as the hormones secreted by it. Therefore, NETs can be difficult to diagnose early. Further tests like CT scans, endoscopies and biopsies are often needed to confirm a NET.

Treatment Based on Tumor Grade and Stage

Treatment for NETs depends on various factors like the grade or aggressiveness of the tumor, the stage or extent of spread, primary site of the tumor and patient health status. NETs are classified as low-grade (grade 1 or 2) or high-grade (grade 3) based on how fast the tumor cells multiply and spread. Low-grade NETs generally have a slower growth rate and better prognosis while high-grade NETs tend to behave more aggressively. For localized low-grade NETs, surgical removal of the tumor is usually the primary treatment approach. While for regional or metastatic low-grade NETs, various locoregional and systemic therapies may be recommended. Treatment for high-grade NETs often involves a combination of chemotherapy and other therapies.

Surgical Removal of Small Primary Tumors

Surgery remains the mainstay of treatment for localized, low-grade Neuroendocrine Tumor Treatment that are still confined to the organ of origin. The aim of surgery is to completely remove (resect) the primary tumor along with some surrounding healthy tissue and lymph nodes. The type of surgery depends on the location and size of the tumor. For example, resection of part of stomach (gastric resection) or intestinal segment (intestinal resection) may be done for gastrointestinal NETs. While for pancreatic NETs, distal pancreatectomy (removal of tail of pancreas) or pancreaticoduodenectomy (Whipple procedure) may be performed. Surgical removal offers the best chance of cure for patients with localized disease and can provide long-term control in many cases.

Managing Lymph Node Spread and Distant Metastases

For low-grade NETs that have spread to nearby lymph nodes or other distant organs, additional treatments beyond surgery may be needed for better management and control of the cancer. Common options include somatostatin analogs, targeted drug therapy, liver-directed therapy, ablation and others. Somatostatin analogs like Octreotide and Lanreotide work by limiting the secretion of hormones from NETs and slowing tumor growth. Targeted drugs like Sunitinib and Everolimus interfere with molecular pathways important for cancer growth. Liver-directed therapies such as embolization, radiofrequency ablation or chemoembolization are used to treat NET liver metastases. These therapies can help control symptoms, halt tumor growth and potentially prolong survival for patients with advanced disease. Careful monitoring is important after treatment to detect any recurrence early.

The Role of Chemotherapy for High-grade Tumors

For high-grade, rapidly growing NETs where surgical removal may not be adequate or possible, chemotherapy plays a bigger treatment role. Platinum-based chemotherapy regimens containing drugs like Cisplatin and Carboplatin given systemically are commonly used. The addition of other chemotherapy drugs like Streptozocin, 5-Fluorouracil and Doxorubicin have also shown activity against high-grade NETs. More recently, targeted therapies like Sunitinib, Everolimus and Capecitabine have demonstrated benefit in clinical trials for advanced high-grade disease and are increasingly being used. Aggressive locoregional treatments along with medical management is recommended for these very malignant NETs. While cure may not always be possible, treatment aims to slow tumor progression and manage symptoms.

Future Treatment Advances

With growing research on the molecular drivers of NETs, new targeted drugs and immunotherapies are being developed. Some promising treatments are currently under investigation in clinical trials. Peptide receptor radionuclide therapy uses radiolabeled somatostatin analogs to selectively deliver radiation to tumors and has shown response in certain patients. Gene therapies involving gene modifications may help sensitize NETs to immunotherapy. Checkpoint inhibitors blocking immune checkpoints like PD-1 and CTLA-4 are also being tested. Novel targeted therapies inhibiting key pathways and genes altered in NETs show early efficacy. Personalized medicine approaches using advanced molecular profiling to guide treatment selection hold promise for future management of NETs. Continued research efforts aim to harness these new therapies and improve long-term outcomes for patients across all stages of NETs.

NETs encompass a diverse group of rare neuroendocrine cancers that arise from cells involved in hormone production across the body. While challenging to diagnose and treat, improved understanding of NET biology coupled with treatment advances have significantly enhanced patient outcomes and survival. Treatment is tailored based on tumor grade, extent of disease and other factors. Surgery takes precedence for localized low-grade tumors while various systemic and locoregional options work well for advanced stages. Future research aims to establish new guidelines and bring novel targeted and immune therapies into NET management to better help patients living with these rare cancers.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it